Lansforsakringar Fondforvaltning AB publ Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Lansforsakringar Fondforvaltning AB publ bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 42,544 shares of the biopharmaceutical company’s stock, valued at approximately $10,011,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Allworth Financial LP increased its stake in shares of Alnylam Pharmaceuticals by 6.8% during the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 38 shares during the period. Investment Management Corp of Ontario increased its stake in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock valued at $1,670,000 after buying an additional 40 shares during the period. Nixon Peabody Trust Co. increased its stake in shares of Alnylam Pharmaceuticals by 1.9% during the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock valued at $540,000 after buying an additional 43 shares during the period. Brevan Howard Capital Management LP boosted its position in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 44 shares in the last quarter. Finally, IFP Advisors Inc boosted its position in Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.6%

Alnylam Pharmaceuticals stock opened at $285.56 on Thursday. The stock has a market capitalization of $37.23 billion, a PE ratio of -131.59 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a 12 month low of $146.79 and a 12 month high of $304.39. The business has a 50 day simple moving average of $259.87 and a 200-day simple moving average of $254.74. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals’s quarterly revenue was up 20.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.16) EPS. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday, March 21st. Redburn Atlantic assumed coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a “buy” rating and a $353.00 target price for the company. Bank of America upped their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a report on Friday, March 21st. Finally, Wall Street Zen raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $319.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.